Crocus Technology Secures $45m Series D

Crocus Technology, a developer of magnetically enhanced semiconductor technologies for mobile security, embedded microcontrollers, harsh environment electronics and magnetic sensors, has raised 34 million euros ($45 million) in additional capital. A new private investor, Industrial Investors, joined the round led by Idinvest Partners. Major investors Sofinnova Ventures, Innovation Capital, Nanodimension and Ventech also participated.

Guavus Acquires Neuralitic Systems

Guavus, a provider of big data analytics solutions, has acquired Neuralitic Systems, a mobile data monetization and marketing analytics experts serving the telecommunications industry. Guavus is backed by Investor Growth Capital, QuestMark Partners and previous investors Artiman Ventures, Sofinnova Ventures and Intel Capital.

Guavus Raises $30m Funding

Guavus, a provider of big data analytics solutions has closed a $30 million round of new funding. Investor Growth Capital led the round with participation from QuestMark Partners and previous investors Artiman Ventures, Sofinnova Ventures and Intel Capital.

Salveo Completes Additional Financings and Acquisition

Specialty pharmacy company Salveo Specialty Pharmacy has completed a second round of equity and debt funding and the subsequent acquisition of Mission Road Pharmacy. Salveo Specialty Pharmacy is backed by Three Arch Partners, NewSpring Capital and Petra Capital Partners. The additional equity financing was led by new investor Sofinnova Ventures. The debt financing included additional subordinated debt provided by Petra, as well as a new senior credit facility provided by Regions Bank.

Phizer Buys VC-Backed NextWave Pharmaceuticals

Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round last January.

Cebix Incorporated Inks $30.9m Series C and Appoints President and CEO

Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, has secured a $30.9M Series B investment. Prior investors InterWest, Sofinnova Ventures and Thomas, McNerney & Partners all participated in the financing. The company has also appointed Dr. Joel Martin as president and CEO.

peHUB First Read

Everyone, please meet Radish the cat, peHUB’s new intern. We’re still training her to fetch coffee. Or, anything.

Alimera Sciences Inks $40m Series A led by Palo Alto Investors

Alimera Sciences, a biopharmaceutical company specialising in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has secured a $40 million Series A financing. Palo Alto Investors acted as the lead investor in the offering, with Sofinnova Ventures and New Enterprise Associates also participating. PRESS RELEASE Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that […]

Catalyst Biosciences Inks $7M from Phizer

Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.

Takeda Pharmaceutical Buys VC-Backed Intellikine

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

peHUB First Read

Cowa-Bunga-Bunga: Berlusconi’s outta here!

L’Chaim! Sofinnova Ventures eyes Israel

Back in Action: SAC Capital spinoff Siris

They’ll be Back: Occupy Zuccotti protestors plot NY-to-DC march

Me, Too! Now Yelp wants to go public

Fund Founded: Thiel’s fund said to be raising up to $600 million

Stashing the Cash: JC Flowers weathers global market turmoil

Cloud’s Silver Lining: CX.com start-up rolls out new product and boosts management team

Bring it Back: Back9 boosts funding round

A Healthy Start: Healthcare resource start-up Kyruus raises $3 million

Intellikine Adds $4M in Milestone Payments

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Sofinnova Closes $440M Eighth Fund

Sofinnova Ventures has closed its eighth fund, Sofinnova Venture Partners VIII, with a total of $440 million in commitments and a sharpened focus on clinical-stage drug companies. The firm began fundraising in February, and held a first close four months later, says general partner Garheng Kong. Unlike the firm’s previous fund, which included investments in […]

Mobile Ad Firm Blyk Names Insider Eric Kip as CEO

Blyk, a mobile ad firm, has promoted chief commercial officer Eric Kip to the post of chief executive, replacing Blyk cofounder Pekka Ala-Pietila. Blyk, which has offices in Helsinki, London, Amsterdam, and Delhi, has raised €87M since its 2006 founding, including from Sofinnova Ventures, Goldman Sachs, and Nexit Ventures. REUTERS: Blyk, a pioneer in the mobile-telephone advertising business, said […]

Allergan Buys Vicept Therapeutics

Allergan is buying privately held dermatology company Vicept Therapeutics. Formed in 2009, Vicept is backed by investors including Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Under the terms of the acquisition, which is expected to close during the third quarter, Allergan will pay $75 million in cash up-front, as well as up to $200 million in payments tied to specific milestones.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget